Blood–brain barrier endothelial cell surface receptors

Blood–brain barrier (BBB) endothelial cell surface receptors are a diverse group of proteins expressed on the luminal and abluminal membranes of brain microvascular endothelial cells [1.1.1][1.3.1]. These receptors, including the transferrin receptor (TfR), insulin receptor (IR), and low-density lipoprotein receptor-related protein 1 (LRP1), are essential for the selective transport of nutrients and signaling molecules into the brain [1.2.1][1.3.2]. In pharmacology, they are primarily exploited as portals for drug delivery, where therapeutic agents are engineered to bind these receptors and undergo receptor-mediated transcytosis (RMT) to bypass the restrictive barrier [1.1.4][1.2.3]. Beyond transport, these receptors participate in signal transduction and cell adhesion, influencing neurovascular integrity and immune cell trafficking [1.3.1][1.3.3]. Dysregulation of these receptors is implicated in the pathogenesis of neurodegenerative diseases, brain tumors, and neuroinflammatory conditions [1.1.2][1.3.5]. However, targeting these receptors presents significant challenges, including potential off-target effects in peripheral tissues where these receptors are also expressed and the risk of interfering with vital physiological transport processes [1.2.4][1.3.1].

Other names

RMT receptorsReceptor-mediated transcytosis receptorsBrain endothelial cell surface proteinsBBB transcytosis receptorsBBB-ECSRs

Receptor-mediated transcytosis (RMT) is the primary mechanism for transporting large molecules across the BBB via these receptors, involving ligand binding, endocytosis, intracellular trafficking, and exocytosis at the abluminal membrane [1.2.2][1.2.4]. Other mechanisms include carrier-mediated transport (CMT) for small molecules and signal transduction modulation to regulate barrier permeability [1.2.1][1.3.1].